End-of-day quote
Casablanca S.E.
06:00:00 2024-07-14 pm EDT
|
5-day change
|
1st Jan Change
|
955
MAD
|
-1.55%
|
|
-3.54%
|
+0.42%
|
Fiscal Period: December |
2019
|
2020
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
2,918
|
3,600
|
6,847
|
6,876
|
-
|
Enterprise Value (EV)
1 |
2,918
|
3,889
|
6,847
|
6,876
|
6,876
|
P/E ratio
|
13.6
x
|
15.6
x
|
26.1
x
|
24.6
x
|
22.1
x
|
Yield
|
-
|
1.05%
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
1,989,042
x
|
-
|
-
|
-
|
EV / Revenue
|
-
|
1,989,042
x
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
9,799,863
x
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
4.25
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
7,200
|
7,200
|
7,200
|
7,200
|
-
|
Reference price
2 |
405.2
|
500.0
|
951.0
|
955.0
|
955.0
|
Announcement Date
|
5/1/21
|
4/30/21
|
4/19/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2023
|
2024
|
2025
|
---|
Net sales
|
-
|
1,810
|
-
|
-
|
-
|
EBITDA
|
-
|
367.4
|
-
|
-
|
-
|
EBIT
|
-
|
366
|
-
|
-
|
-
|
Operating Margin
|
-
|
20.22%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
238.2
|
-
|
-
|
-
|
Net margin
|
-
|
13.16%
|
-
|
-
|
-
|
EPS
1 |
29.77
|
32.00
|
36.50
|
38.80
|
43.20
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
5.250
|
-
|
-
|
-
|
Announcement Date
|
5/1/21
|
4/30/21
|
4/19/24
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
194
|
155
|
289
|
136
|
302
|
448
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.7103
x
|
-
|
0.6725
x
|
0.2657
x
|
0.5649
x
|
1.01
x
|
Free Cash Flow
1 |
57.4
|
102
|
40.2
|
339
|
67.6
|
-63.8
|
ROE (net income / shareholders' equity)
|
29.4%
|
25.4%
|
20.6%
|
22.3%
|
19.6%
|
17.9%
|
ROA (Net income/ Total Assets)
|
12.3%
|
13.6%
|
12.5%
|
13.8%
|
13.1%
|
9.46%
|
Assets
1 |
1,766
|
1,571
|
1,835
|
2,014
|
2,032
|
2,779
|
Book Value Per Share
|
-
|
124.0
|
163.0
|
180.0
|
197.0
|
208.0
|
Cash Flow per Share
|
-
|
4.240
|
3.570
|
12.20
|
6.240
|
6.640
|
Capex
1 |
48.3
|
31.4
|
59.2
|
62.6
|
70.1
|
118
|
Capex / Sales
|
3.04%
|
1.84%
|
3.29%
|
3.04%
|
3.05%
|
4.73%
|
Announcement Date
|
2/4/21
|
2/4/21
|
5/1/21
|
4/15/22
|
4/29/23
|
4/19/24
|
|
1st Jan change
|
Capi.
|
---|
| +0.42% | 699M | | +61.53% | 848B | | +33.25% | 627B | | -3.66% | 363B | | +15.06% | 318B | | +9.18% | 299B | | +12.35% | 234B | | +16.18% | 225B | | +15.67% | 179B | | +2.47% | 167B |
Other Pharmaceuticals
|